CYL Stock Overview
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.12 |
| 52 Week High | US$19.94 |
| 52 Week Low | US$11.70 |
| Beta | 1.67 |
| 1 Month Change | -2.94% |
| 3 Month Change | 24.16% |
| 1 Year Change | 59.33% |
| 3 Year Change | -19.66% |
| 5 Year Change | -32.96% |
| Change since IPO | 366.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -1.2% | -1.2% |
| 1Y | 59.3% | -10.6% | 1.8% |
Return vs Industry: CYL exceeded the German Medical Equipment industry which returned -9.6% over the past year.
Return vs Market: CYL exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| CYL volatility | |
|---|---|
| CYL Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CYL has not had significant price volatility in the past 3 months.
Volatility Over Time: CYL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,500 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Artivion, Inc. Fundamentals Summary
| CYL fundamental statistics | |
|---|---|
| Market cap | €767.04m |
| Earnings (TTM) | -€28.65m |
| Revenue (TTM) | €331.81m |
2.3x
P/S Ratio-26.8x
P/E RatioIs CYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYL income statement (TTM) | |
|---|---|
| Revenue | US$354.00m |
| Cost of Revenue | US$124.83m |
| Gross Profit | US$229.18m |
| Other Expenses | US$259.74m |
| Earnings | -US$30.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 64.74% |
| Net Profit Margin | -8.63% |
| Debt/Equity Ratio | 108.9% |
How did CYL perform over the long term?
See historical performance and comparison